Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Amylyx Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.